Association Between Hematoma Expansion Severity and Outcome and Its Interaction With Baseline Intracerebral Hemorrhage Volume

Hematoma expansion (HE) is a major determinant of neurologic deterioration and poor outcome in intracerebral hemorrhage (ICH) and represents an appealing therapeutic target. We analyzed the prognostic effect of different degrees of HE. This was a retrospective analysis of patients with ICH admitted...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neurology 2023-10, Vol.101 (16), p.e1606-e1613
Hauptverfasser: Morotti, Andrea, Boulouis, Gregoire, Nawabi, Jawed, Li, Qi, Charidimou, Andreas, Pasi, Marco, Schlunk, Frieder, Shoamanesh, Ashkan, Katsanos, Aristeidis H, Mazzacane, Federico, Busto, Giorgio, Arba, Francesco, Brancaleoni, Laura, Giacomozzi, Sebastiano, Simonetti, Luigi, Warren, Andrew D, Laudisi, Michele, Cavallini, Anna, Gurol, M Edip, Viswanathan, Anand, Zini, Andrea, Casetta, Ilaria, Fainardi, Enrico, Greenberg, Steven M, Padovani, Alessandro, Rosand, Jonathan, Goldstein, Joshua N
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page e1613
container_issue 16
container_start_page e1606
container_title Neurology
container_volume 101
creator Morotti, Andrea
Boulouis, Gregoire
Nawabi, Jawed
Li, Qi
Charidimou, Andreas
Pasi, Marco
Schlunk, Frieder
Shoamanesh, Ashkan
Katsanos, Aristeidis H
Mazzacane, Federico
Busto, Giorgio
Arba, Francesco
Brancaleoni, Laura
Giacomozzi, Sebastiano
Simonetti, Luigi
Warren, Andrew D
Laudisi, Michele
Cavallini, Anna
Gurol, M Edip
Viswanathan, Anand
Zini, Andrea
Casetta, Ilaria
Fainardi, Enrico
Greenberg, Steven M
Padovani, Alessandro
Rosand, Jonathan
Goldstein, Joshua N
description Hematoma expansion (HE) is a major determinant of neurologic deterioration and poor outcome in intracerebral hemorrhage (ICH) and represents an appealing therapeutic target. We analyzed the prognostic effect of different degrees of HE. This was a retrospective analysis of patients with ICH admitted at 8 academic institutions in Italy, Germany, Canada, China, and the United States. All patients underwent baseline and follow-up imaging for HE assessment. Relative HE (rHE) was classified as follows: none (66%). Absolute HE (aHE) was classified as none (12.5 mL). Predictors of poor functional outcome (90 days modified Rankin Scale 4-6) were explored with logistic regression. We included 2,163 patients, of whom 1,211 (56.0%) had poor outcome. The occurrence of severe aHE or rHE was more common in patients with unfavorable outcome (13.9% vs 6.5%, < 0.001 and 18.3% vs 7.2%, < 0.001 respectively). This association was confirmed in logistic regression (rHE odds ratio [OR] 1.98, 95% CI 1.38-2.82, < 0.001; aHE OR 1.73, 95% CI 1.23-2.45, = 0.002) while there was no association between mild or moderate HE and poor outcome. The association between severe HE and poor outcome was significant only in patients with baseline ICH volume below 30 mL. The strongest association between HE and outcome was observed in patients with smaller initial volume experiencing severe HE. These findings may inform clinical trial design and guide clinicians in selecting patients for antiexpansion therapies.
doi_str_mv 10.1212/WNL.0000000000207728
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10585678</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2854967721</sourcerecordid><originalsourceid>FETCH-LOGICAL-c363t-1fbc0e9dd4f5650aee803bd85d60a0d1ad3d13fed9506c96c811980091cedc353</originalsourceid><addsrcrecordid>eNpdkU1P4zAQhi0EgsLyDxDKkUtYO64d54QAwbZSBYeFhZvl2hNqlMTFdmB74L-vw0cF64uteWcej_QgdEDwMSlI8fPuanaM16fAZVmIDTQirOA5p8X9JhqlssipKMUO2g3hEeMUltU22qElx2POyQi9nobgtFXRui47g_gC0GUTaFV0rcou_i5VF4boNzyDt3GVqc5k133UroW39zSGbNpF8Eq_Me5sXGRnKkBjOxiSFICHuVfNwHXeL9QDZH9c07fwA23Vqgmw_3HvodvLi5vzST67_jU9P53lmnIac1LPNYbKmHHNOMMKQGA6N4IZjhU2RBlqCK3BVAxzXXEtCKkExhXRYDRldA-dvHOX_bxNJRjWauTS21b5lXTKyu9JZxfywT1LgplgvBSJcPRB8O6phxBla4OGplEduD7IQrBxxZMDklrH763auxA81Ot_CJaDOpnUyf_VpbHDrzuuhz5d0X8fbZg0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2854967721</pqid></control><display><type>article</type><title>Association Between Hematoma Expansion Severity and Outcome and Its Interaction With Baseline Intracerebral Hemorrhage Volume</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><source>Alma/SFX Local Collection</source><creator>Morotti, Andrea ; Boulouis, Gregoire ; Nawabi, Jawed ; Li, Qi ; Charidimou, Andreas ; Pasi, Marco ; Schlunk, Frieder ; Shoamanesh, Ashkan ; Katsanos, Aristeidis H ; Mazzacane, Federico ; Busto, Giorgio ; Arba, Francesco ; Brancaleoni, Laura ; Giacomozzi, Sebastiano ; Simonetti, Luigi ; Warren, Andrew D ; Laudisi, Michele ; Cavallini, Anna ; Gurol, M Edip ; Viswanathan, Anand ; Zini, Andrea ; Casetta, Ilaria ; Fainardi, Enrico ; Greenberg, Steven M ; Padovani, Alessandro ; Rosand, Jonathan ; Goldstein, Joshua N</creator><creatorcontrib>Morotti, Andrea ; Boulouis, Gregoire ; Nawabi, Jawed ; Li, Qi ; Charidimou, Andreas ; Pasi, Marco ; Schlunk, Frieder ; Shoamanesh, Ashkan ; Katsanos, Aristeidis H ; Mazzacane, Federico ; Busto, Giorgio ; Arba, Francesco ; Brancaleoni, Laura ; Giacomozzi, Sebastiano ; Simonetti, Luigi ; Warren, Andrew D ; Laudisi, Michele ; Cavallini, Anna ; Gurol, M Edip ; Viswanathan, Anand ; Zini, Andrea ; Casetta, Ilaria ; Fainardi, Enrico ; Greenberg, Steven M ; Padovani, Alessandro ; Rosand, Jonathan ; Goldstein, Joshua N</creatorcontrib><description>Hematoma expansion (HE) is a major determinant of neurologic deterioration and poor outcome in intracerebral hemorrhage (ICH) and represents an appealing therapeutic target. We analyzed the prognostic effect of different degrees of HE. This was a retrospective analysis of patients with ICH admitted at 8 academic institutions in Italy, Germany, Canada, China, and the United States. All patients underwent baseline and follow-up imaging for HE assessment. Relative HE (rHE) was classified as follows: none (&lt;0%), mild (0%-33%), moderate (33.1%-66%), and severe (&gt;66%). Absolute HE (aHE) was classified as none (&lt;0 mL), mild (0-6.0 mL), moderate (6.1-12.5 mL), and severe (&gt;12.5 mL). Predictors of poor functional outcome (90 days modified Rankin Scale 4-6) were explored with logistic regression. We included 2,163 patients, of whom 1,211 (56.0%) had poor outcome. The occurrence of severe aHE or rHE was more common in patients with unfavorable outcome (13.9% vs 6.5%, &lt; 0.001 and 18.3% vs 7.2%, &lt; 0.001 respectively). This association was confirmed in logistic regression (rHE odds ratio [OR] 1.98, 95% CI 1.38-2.82, &lt; 0.001; aHE OR 1.73, 95% CI 1.23-2.45, = 0.002) while there was no association between mild or moderate HE and poor outcome. The association between severe HE and poor outcome was significant only in patients with baseline ICH volume below 30 mL. The strongest association between HE and outcome was observed in patients with smaller initial volume experiencing severe HE. These findings may inform clinical trial design and guide clinicians in selecting patients for antiexpansion therapies.</description><identifier>ISSN: 0028-3878</identifier><identifier>ISSN: 1526-632X</identifier><identifier>EISSN: 1526-632X</identifier><identifier>DOI: 10.1212/WNL.0000000000207728</identifier><identifier>PMID: 37604661</identifier><language>eng</language><publisher>United States: Lippincott Williams &amp; Wilkins</publisher><subject>Cerebral Hemorrhage - drug therapy ; Cerebral Hemorrhage - therapy ; Hematoma - drug therapy ; Hematoma - therapy ; Humans ; Prognosis ; Retrospective Studies ; Tomography, X-Ray Computed</subject><ispartof>Neurology, 2023-10, Vol.101 (16), p.e1606-e1613</ispartof><rights>2023 American Academy of Neurology.</rights><rights>2023 American Academy of Neurology 2023 American Academy of Neurology</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c363t-1fbc0e9dd4f5650aee803bd85d60a0d1ad3d13fed9506c96c811980091cedc353</citedby><cites>FETCH-LOGICAL-c363t-1fbc0e9dd4f5650aee803bd85d60a0d1ad3d13fed9506c96c811980091cedc353</cites><orcidid>0000-0002-6406-1828 ; 0000-0001-8422-9205 ; 0000-0002-9144-148X ; 0000-0002-6558-1155 ; 0000-0003-3941-7383 ; 0000-0003-1792-8887 ; 0000-0001-5891-337X ; 0000-0001-9976-2459</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,780,784,885,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37604661$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Morotti, Andrea</creatorcontrib><creatorcontrib>Boulouis, Gregoire</creatorcontrib><creatorcontrib>Nawabi, Jawed</creatorcontrib><creatorcontrib>Li, Qi</creatorcontrib><creatorcontrib>Charidimou, Andreas</creatorcontrib><creatorcontrib>Pasi, Marco</creatorcontrib><creatorcontrib>Schlunk, Frieder</creatorcontrib><creatorcontrib>Shoamanesh, Ashkan</creatorcontrib><creatorcontrib>Katsanos, Aristeidis H</creatorcontrib><creatorcontrib>Mazzacane, Federico</creatorcontrib><creatorcontrib>Busto, Giorgio</creatorcontrib><creatorcontrib>Arba, Francesco</creatorcontrib><creatorcontrib>Brancaleoni, Laura</creatorcontrib><creatorcontrib>Giacomozzi, Sebastiano</creatorcontrib><creatorcontrib>Simonetti, Luigi</creatorcontrib><creatorcontrib>Warren, Andrew D</creatorcontrib><creatorcontrib>Laudisi, Michele</creatorcontrib><creatorcontrib>Cavallini, Anna</creatorcontrib><creatorcontrib>Gurol, M Edip</creatorcontrib><creatorcontrib>Viswanathan, Anand</creatorcontrib><creatorcontrib>Zini, Andrea</creatorcontrib><creatorcontrib>Casetta, Ilaria</creatorcontrib><creatorcontrib>Fainardi, Enrico</creatorcontrib><creatorcontrib>Greenberg, Steven M</creatorcontrib><creatorcontrib>Padovani, Alessandro</creatorcontrib><creatorcontrib>Rosand, Jonathan</creatorcontrib><creatorcontrib>Goldstein, Joshua N</creatorcontrib><title>Association Between Hematoma Expansion Severity and Outcome and Its Interaction With Baseline Intracerebral Hemorrhage Volume</title><title>Neurology</title><addtitle>Neurology</addtitle><description>Hematoma expansion (HE) is a major determinant of neurologic deterioration and poor outcome in intracerebral hemorrhage (ICH) and represents an appealing therapeutic target. We analyzed the prognostic effect of different degrees of HE. This was a retrospective analysis of patients with ICH admitted at 8 academic institutions in Italy, Germany, Canada, China, and the United States. All patients underwent baseline and follow-up imaging for HE assessment. Relative HE (rHE) was classified as follows: none (&lt;0%), mild (0%-33%), moderate (33.1%-66%), and severe (&gt;66%). Absolute HE (aHE) was classified as none (&lt;0 mL), mild (0-6.0 mL), moderate (6.1-12.5 mL), and severe (&gt;12.5 mL). Predictors of poor functional outcome (90 days modified Rankin Scale 4-6) were explored with logistic regression. We included 2,163 patients, of whom 1,211 (56.0%) had poor outcome. The occurrence of severe aHE or rHE was more common in patients with unfavorable outcome (13.9% vs 6.5%, &lt; 0.001 and 18.3% vs 7.2%, &lt; 0.001 respectively). This association was confirmed in logistic regression (rHE odds ratio [OR] 1.98, 95% CI 1.38-2.82, &lt; 0.001; aHE OR 1.73, 95% CI 1.23-2.45, = 0.002) while there was no association between mild or moderate HE and poor outcome. The association between severe HE and poor outcome was significant only in patients with baseline ICH volume below 30 mL. The strongest association between HE and outcome was observed in patients with smaller initial volume experiencing severe HE. These findings may inform clinical trial design and guide clinicians in selecting patients for antiexpansion therapies.</description><subject>Cerebral Hemorrhage - drug therapy</subject><subject>Cerebral Hemorrhage - therapy</subject><subject>Hematoma - drug therapy</subject><subject>Hematoma - therapy</subject><subject>Humans</subject><subject>Prognosis</subject><subject>Retrospective Studies</subject><subject>Tomography, X-Ray Computed</subject><issn>0028-3878</issn><issn>1526-632X</issn><issn>1526-632X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkU1P4zAQhi0EgsLyDxDKkUtYO64d54QAwbZSBYeFhZvl2hNqlMTFdmB74L-vw0cF64uteWcej_QgdEDwMSlI8fPuanaM16fAZVmIDTQirOA5p8X9JhqlssipKMUO2g3hEeMUltU22qElx2POyQi9nobgtFXRui47g_gC0GUTaFV0rcou_i5VF4boNzyDt3GVqc5k133UroW39zSGbNpF8Eq_Me5sXGRnKkBjOxiSFICHuVfNwHXeL9QDZH9c07fwA23Vqgmw_3HvodvLi5vzST67_jU9P53lmnIac1LPNYbKmHHNOMMKQGA6N4IZjhU2RBlqCK3BVAxzXXEtCKkExhXRYDRldA-dvHOX_bxNJRjWauTS21b5lXTKyu9JZxfywT1LgplgvBSJcPRB8O6phxBla4OGplEduD7IQrBxxZMDklrH763auxA81Ot_CJaDOpnUyf_VpbHDrzuuhz5d0X8fbZg0</recordid><startdate>20231017</startdate><enddate>20231017</enddate><creator>Morotti, Andrea</creator><creator>Boulouis, Gregoire</creator><creator>Nawabi, Jawed</creator><creator>Li, Qi</creator><creator>Charidimou, Andreas</creator><creator>Pasi, Marco</creator><creator>Schlunk, Frieder</creator><creator>Shoamanesh, Ashkan</creator><creator>Katsanos, Aristeidis H</creator><creator>Mazzacane, Federico</creator><creator>Busto, Giorgio</creator><creator>Arba, Francesco</creator><creator>Brancaleoni, Laura</creator><creator>Giacomozzi, Sebastiano</creator><creator>Simonetti, Luigi</creator><creator>Warren, Andrew D</creator><creator>Laudisi, Michele</creator><creator>Cavallini, Anna</creator><creator>Gurol, M Edip</creator><creator>Viswanathan, Anand</creator><creator>Zini, Andrea</creator><creator>Casetta, Ilaria</creator><creator>Fainardi, Enrico</creator><creator>Greenberg, Steven M</creator><creator>Padovani, Alessandro</creator><creator>Rosand, Jonathan</creator><creator>Goldstein, Joshua N</creator><general>Lippincott Williams &amp; Wilkins</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-6406-1828</orcidid><orcidid>https://orcid.org/0000-0001-8422-9205</orcidid><orcidid>https://orcid.org/0000-0002-9144-148X</orcidid><orcidid>https://orcid.org/0000-0002-6558-1155</orcidid><orcidid>https://orcid.org/0000-0003-3941-7383</orcidid><orcidid>https://orcid.org/0000-0003-1792-8887</orcidid><orcidid>https://orcid.org/0000-0001-5891-337X</orcidid><orcidid>https://orcid.org/0000-0001-9976-2459</orcidid></search><sort><creationdate>20231017</creationdate><title>Association Between Hematoma Expansion Severity and Outcome and Its Interaction With Baseline Intracerebral Hemorrhage Volume</title><author>Morotti, Andrea ; Boulouis, Gregoire ; Nawabi, Jawed ; Li, Qi ; Charidimou, Andreas ; Pasi, Marco ; Schlunk, Frieder ; Shoamanesh, Ashkan ; Katsanos, Aristeidis H ; Mazzacane, Federico ; Busto, Giorgio ; Arba, Francesco ; Brancaleoni, Laura ; Giacomozzi, Sebastiano ; Simonetti, Luigi ; Warren, Andrew D ; Laudisi, Michele ; Cavallini, Anna ; Gurol, M Edip ; Viswanathan, Anand ; Zini, Andrea ; Casetta, Ilaria ; Fainardi, Enrico ; Greenberg, Steven M ; Padovani, Alessandro ; Rosand, Jonathan ; Goldstein, Joshua N</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c363t-1fbc0e9dd4f5650aee803bd85d60a0d1ad3d13fed9506c96c811980091cedc353</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Cerebral Hemorrhage - drug therapy</topic><topic>Cerebral Hemorrhage - therapy</topic><topic>Hematoma - drug therapy</topic><topic>Hematoma - therapy</topic><topic>Humans</topic><topic>Prognosis</topic><topic>Retrospective Studies</topic><topic>Tomography, X-Ray Computed</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Morotti, Andrea</creatorcontrib><creatorcontrib>Boulouis, Gregoire</creatorcontrib><creatorcontrib>Nawabi, Jawed</creatorcontrib><creatorcontrib>Li, Qi</creatorcontrib><creatorcontrib>Charidimou, Andreas</creatorcontrib><creatorcontrib>Pasi, Marco</creatorcontrib><creatorcontrib>Schlunk, Frieder</creatorcontrib><creatorcontrib>Shoamanesh, Ashkan</creatorcontrib><creatorcontrib>Katsanos, Aristeidis H</creatorcontrib><creatorcontrib>Mazzacane, Federico</creatorcontrib><creatorcontrib>Busto, Giorgio</creatorcontrib><creatorcontrib>Arba, Francesco</creatorcontrib><creatorcontrib>Brancaleoni, Laura</creatorcontrib><creatorcontrib>Giacomozzi, Sebastiano</creatorcontrib><creatorcontrib>Simonetti, Luigi</creatorcontrib><creatorcontrib>Warren, Andrew D</creatorcontrib><creatorcontrib>Laudisi, Michele</creatorcontrib><creatorcontrib>Cavallini, Anna</creatorcontrib><creatorcontrib>Gurol, M Edip</creatorcontrib><creatorcontrib>Viswanathan, Anand</creatorcontrib><creatorcontrib>Zini, Andrea</creatorcontrib><creatorcontrib>Casetta, Ilaria</creatorcontrib><creatorcontrib>Fainardi, Enrico</creatorcontrib><creatorcontrib>Greenberg, Steven M</creatorcontrib><creatorcontrib>Padovani, Alessandro</creatorcontrib><creatorcontrib>Rosand, Jonathan</creatorcontrib><creatorcontrib>Goldstein, Joshua N</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Morotti, Andrea</au><au>Boulouis, Gregoire</au><au>Nawabi, Jawed</au><au>Li, Qi</au><au>Charidimou, Andreas</au><au>Pasi, Marco</au><au>Schlunk, Frieder</au><au>Shoamanesh, Ashkan</au><au>Katsanos, Aristeidis H</au><au>Mazzacane, Federico</au><au>Busto, Giorgio</au><au>Arba, Francesco</au><au>Brancaleoni, Laura</au><au>Giacomozzi, Sebastiano</au><au>Simonetti, Luigi</au><au>Warren, Andrew D</au><au>Laudisi, Michele</au><au>Cavallini, Anna</au><au>Gurol, M Edip</au><au>Viswanathan, Anand</au><au>Zini, Andrea</au><au>Casetta, Ilaria</au><au>Fainardi, Enrico</au><au>Greenberg, Steven M</au><au>Padovani, Alessandro</au><au>Rosand, Jonathan</au><au>Goldstein, Joshua N</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Association Between Hematoma Expansion Severity and Outcome and Its Interaction With Baseline Intracerebral Hemorrhage Volume</atitle><jtitle>Neurology</jtitle><addtitle>Neurology</addtitle><date>2023-10-17</date><risdate>2023</risdate><volume>101</volume><issue>16</issue><spage>e1606</spage><epage>e1613</epage><pages>e1606-e1613</pages><issn>0028-3878</issn><issn>1526-632X</issn><eissn>1526-632X</eissn><abstract>Hematoma expansion (HE) is a major determinant of neurologic deterioration and poor outcome in intracerebral hemorrhage (ICH) and represents an appealing therapeutic target. We analyzed the prognostic effect of different degrees of HE. This was a retrospective analysis of patients with ICH admitted at 8 academic institutions in Italy, Germany, Canada, China, and the United States. All patients underwent baseline and follow-up imaging for HE assessment. Relative HE (rHE) was classified as follows: none (&lt;0%), mild (0%-33%), moderate (33.1%-66%), and severe (&gt;66%). Absolute HE (aHE) was classified as none (&lt;0 mL), mild (0-6.0 mL), moderate (6.1-12.5 mL), and severe (&gt;12.5 mL). Predictors of poor functional outcome (90 days modified Rankin Scale 4-6) were explored with logistic regression. We included 2,163 patients, of whom 1,211 (56.0%) had poor outcome. The occurrence of severe aHE or rHE was more common in patients with unfavorable outcome (13.9% vs 6.5%, &lt; 0.001 and 18.3% vs 7.2%, &lt; 0.001 respectively). This association was confirmed in logistic regression (rHE odds ratio [OR] 1.98, 95% CI 1.38-2.82, &lt; 0.001; aHE OR 1.73, 95% CI 1.23-2.45, = 0.002) while there was no association between mild or moderate HE and poor outcome. The association between severe HE and poor outcome was significant only in patients with baseline ICH volume below 30 mL. The strongest association between HE and outcome was observed in patients with smaller initial volume experiencing severe HE. These findings may inform clinical trial design and guide clinicians in selecting patients for antiexpansion therapies.</abstract><cop>United States</cop><pub>Lippincott Williams &amp; Wilkins</pub><pmid>37604661</pmid><doi>10.1212/WNL.0000000000207728</doi><orcidid>https://orcid.org/0000-0002-6406-1828</orcidid><orcidid>https://orcid.org/0000-0001-8422-9205</orcidid><orcidid>https://orcid.org/0000-0002-9144-148X</orcidid><orcidid>https://orcid.org/0000-0002-6558-1155</orcidid><orcidid>https://orcid.org/0000-0003-3941-7383</orcidid><orcidid>https://orcid.org/0000-0003-1792-8887</orcidid><orcidid>https://orcid.org/0000-0001-5891-337X</orcidid><orcidid>https://orcid.org/0000-0001-9976-2459</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0028-3878
ispartof Neurology, 2023-10, Vol.101 (16), p.e1606-e1613
issn 0028-3878
1526-632X
1526-632X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10585678
source MEDLINE; Journals@Ovid Complete; Alma/SFX Local Collection
subjects Cerebral Hemorrhage - drug therapy
Cerebral Hemorrhage - therapy
Hematoma - drug therapy
Hematoma - therapy
Humans
Prognosis
Retrospective Studies
Tomography, X-Ray Computed
title Association Between Hematoma Expansion Severity and Outcome and Its Interaction With Baseline Intracerebral Hemorrhage Volume
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T17%3A42%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Association%20Between%20Hematoma%20Expansion%20Severity%20and%20Outcome%20and%20Its%20Interaction%20With%20Baseline%20Intracerebral%20Hemorrhage%20Volume&rft.jtitle=Neurology&rft.au=Morotti,%20Andrea&rft.date=2023-10-17&rft.volume=101&rft.issue=16&rft.spage=e1606&rft.epage=e1613&rft.pages=e1606-e1613&rft.issn=0028-3878&rft.eissn=1526-632X&rft_id=info:doi/10.1212/WNL.0000000000207728&rft_dat=%3Cproquest_pubme%3E2854967721%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2854967721&rft_id=info:pmid/37604661&rfr_iscdi=true